Martin Chang MD, PhD, FCAP, FRCPC

Dr. Chang clinical expertise is in the surgical pathology of the breast and gynecologic tract. Currently, at Mount Sinai Hospital (Toronto, Canada), my main research interest is in the clinicopathologic and molecular characterization of breast carcinoma. This includes: evaluation of pathologic predictors of recurrence and treatment response, role of host factors in breast cancer progression, and molecular correlates of structural/histologic changes.
His publications are as follows:
Chang MC, Malowany JI, Mazurkiewicz J, Wood M. “Genetic Heterogeneity” in HER2/neu Testing by Fluorescence in situ Hybridization: A Study of 2522 Cases. Modern Pathology 2012; 25(5):683-88.
Niraula S, Dowling RJO, Ennis M, Chang MC, Done SJ, Hood N, Escallon J, Leong WL, McCready DR, Reedijk M, Stambolic V, Goodwin PJ. Metformin in Early Breast Cancer: A Prospective Window of Opportunity Neoadjuvant Study. Breast Cancer Research and Treatment 2012; 135(3):821-30.
Bethune GC, Mullen JB, Chang MC. HER2 testing of multifocal invasive breast carcinoma: How many blocks are enough? American Journal of Clinical Pathology 2013; 140:588-92
Chang MC, Escallon JM, Colgan TJ. Prognostic significance of a positive axillary lymph node fine-needle aspirate (FNA) in patients with invasive breast carcinoma. Cancer Cytopathology 2014; 122(2):138-144.